| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Email: |
chemcell@hotmail.com |
| Products Intro: |
Product Name:PE-04859989
CAS:34783-48-7
Purity:98% Package:5mg;10mg;50mg;100mg,1g;5g;10g;50g;100g
|
| Company Name: |
ATK CHEMICAL COMPANY LIMITED
|
| Tel: |
3429815786 13301662590 |
| Email: |
sales@atkchemical.com |
| Products Intro: |
CAS:34783-48-7
Purity:98% Package:1G,5G,100G,500g,1kg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PF-04859989;PF 04859989,PF04859989
CAS:34783-48-7
Purity:98% Package:5 mg
|
|
| | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one Basic information |
| Product Name: | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one | | Synonyms: | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one;PF-04859989;PF 04859989,PF04859989;2(1H)-Quinolinone, 3-amino-3,4-dihydro-1-hydroxy-, (3S)-;PE-04859989 | | CAS: | 34783-48-7 | | MF: | C9H10N2O2 | | MW: | 178.19 | | EINECS: | 808-880-5 | | Product Categories: | | | Mol File: | 34783-48-7.mol |  |
| | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one Chemical Properties |
| Boiling point | 361.6±52.0 °C(Predicted) | | density | 1.387±0.06 g/cm3(Predicted) | | pka | 8.37±0.40(Predicted) |
| | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one Usage And Synthesis |
| Enzyme inhibitor | This systemically available KAT II inhibitor (FW = 178.19 g/mol; CAS 34783-48-7; IUPAC: (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1H)- one) irreversibly inhibits kynurenine amino transferase II, or KAT II, with Ki = 23 nM, kinact/Ki 112,000 M–1 s –1 , IC50 = 263 nM, and PartitionCoefficientn-octanol/H2O = 3 x 108. This inhibitor most likely makes an enamine adduct with enzyme-bound pyridoxal-P. Rationale: Kynurenate is a tryptophan-derived endogenous antagonist for glutamate and a7-nicotinic acetylcholine receptors in the brain. Increased levels are observed postmortem in the brains of patients with a range of neurocognitive disorders, including schizophrenia. Kynurenate may well contribute to the cognitive symptoms of these conditions. Pharmacology: PF-04859989 restores glutamate release "transients" evoked by ejections of nicotine into the prefrontal cortex of rats exhibiting elevated kynurenate levels. Systemic administration of PF-04859989 30 min prior to administration of Lkynurenine (but not when administered 30 min after L-kynurenine) restores glutamatergic transients recorded up to 120 min after the administration of the KAT II inhibitor. Furthermore, the KAT-II inhibitor significantly reverses L-kynurenine-induced elevations of brain KYNA levels. The KATII inhibitor does not affect nicotine-evoked glutamatergic transients in rats not pre-treated with L-kynurenine |
| | (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one Preparation Products And Raw materials |
|